Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | MTOR | P42345 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 4/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076273 | 0.90 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3667333 | 0.90 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3668111 | 0.88 | KMT2A (0.36) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL24654507 | 0.81 | PRKDC (0.52) | PRKDCPIK3CAMTORPDE4D | |
| SCHEMBL3672605 | 0.77 | PRKDC (0.41) | PRKDCPIK3CAMTORPDE4D | |
| SCHEMBL5936900 | 0.76 | PLK1 (0.43) | PRKDCPIK3CAMTORKDM4EMEN1 | |
| SCHEMBL15722113 | 0.75 | KMT2A (0.37) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL4076490 | 0.75 | KDM4E (0.35) | PRKDCKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3670197 | 0.74 | PIK3CA (0.35) | PIK3CAMTORKDM4EMEN1ALDH1A1 | |
| SCHEMBL4085785 | 0.73 | KDM4E (0.34) | PRKDCKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PRKDC 171/4885PIK3CA 104/4885MTOR 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.